ConforMIS
323 Vintage Park Drive
Suite C
Foster City
California
94404
United States
Tel: 650-286-4151
Fax: 650-286-4160
Website: http://www.conformis.com/
172 articles about ConforMIS
-
Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition
1/16/2024
On September 5, 2023, restor3d, Inc. finalized its previously announced acquisition of Conformis, Inc. With this merger complete, there is tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopaedic landscape.
-
restor3d Completes Acquisition of Conformis
9/5/2023
restor3d, Inc. and Conformis, Inc. announced that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023.
-
Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d
8/21/2023
Conformis, Inc. announced that leading independent proxy advisory firm, Institutional Shareholder Services Inc., has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d.
-
Conformis Reports Second Quarter 2023 Financial Results
8/2/2023
Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the second quarter ended June 30, 2023.
-
Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash
6/23/2023
restor3d, Inc. and Conformis, Inc. announced that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on June 22, 2023.
-
Conformis Reports First Quarter 2023 Financial Results
5/8/2023
Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the first quarter ended March 31, 2023.
-
Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023
4/13/2023
Conformis, Inc., a leading medical device company that features personalized knee and hip replacement products, announced it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023.
-
Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results
3/1/2023
Conformis, Inc. an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the fourth quarter and year ended December 31, 2022.
-
Conformis, Inc. to Participate in Upcoming March 2023 Investor Conferences
2/21/2023
Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate at two upcoming investor conferences.
-
Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022Company Launches New Advertising Campaign
2/10/2023
Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, provided a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022.
-
Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022
1/23/2023
Conformis, Inc., a leading medical device company that features personalized knee and hip replacement products, announced it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023.
-
Conformis, Inc. Regains Compliance with Nasdaq’s Minimum Bid Price Rule
11/30/2022
Conformis, Inc. announced that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market on Nov 25, 2022 notifying Conformis that, based on the closing bid price of Conformis’ common stock having been $1.00 per share or greater on each of the trading days from Nov 10, 2022 to Nov 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550 and the minimum bid price deficiency matter previously disclosed by Conformis is now closed.
-
Conformis Announces First Procedure Performed Using New Actera™ Hip System
11/29/2022
Conformis, Inc. today announced that the first procedure with the company’s new Actera™ Hip System has been performed.
-
Conformis Announces Full Commercial Launch of Imprint™Conformis’ Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA)
11/17/2022
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced the full commercial launch of its new Imprint™ knee system.
-
Conformis, Inc. Effects 1-for-25 Reverse Stock Split
11/9/2022
Conformis, Inc. announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time.
-
Conformis Reports Third Quarter 2022 Financial Results
11/2/2022
Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the third quarter ended September 30, 2022.
-
Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022
10/5/2022
Conformis, Inc. announced today it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Wednesday, November 2, 2022.
-
Conformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference
8/29/2022
Conformis, Inc. announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
-
Conformis Reports Second Quarter 2022 Financial Results
8/8/2022
Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the second quarter ended June 30, 2022.
-
Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants
8/1/2022
Conformis, Inc., a leading medical device company that features personalized knee and hip replacement products, announced it has entered into a multi-year agreement with Vizient, Inc., the nation's largest member-driven health care performance improvement company.